347 related articles for article (PubMed ID: 30992475)
1. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.
Knox T; Sahakian E; Banik D; Hadley M; Palmer E; Noonepalle S; Kim J; Powers J; Gracia-Hernandez M; Oliveira V; Cheng F; Chen J; Barinka C; Pinilla-Ibarz J; Lee NH; Kozikowski A; Villagra A
Sci Rep; 2019 Apr; 9(1):6136. PubMed ID: 30992475
[TBL] [Abstract][Full Text] [Related]
2. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
3. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
[TBL] [Abstract][Full Text] [Related]
4. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
5. Targeting HDAC6 improves anti-CD47 immunotherapy.
Gracia-Hernandez M; Yende AS; Gajendran N; Alahmadi Z; Li X; Munoz Z; Tan K; Noonepalle S; Shibata M; Villagra A
J Exp Clin Cancer Res; 2024 Feb; 43(1):60. PubMed ID: 38414061
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer.
Yang Y; Li L; Jiang Z; Wang B; Pan Z
Cancer Immunol Immunother; 2020 Dec; 69(12):2523-2532. PubMed ID: 32577817
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
8. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
9. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
10. The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer.
Cai J; Qi Q; Qian X; Han J; Zhu X; Zhang Q; Xia R
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1377-1385. PubMed ID: 30963235
[TBL] [Abstract][Full Text] [Related]
11. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
Woods DM; Sodré AL; Villagra A; Sarnaik A; Sotomayor EM; Weber J
Cancer Immunol Res; 2015 Dec; 3(12):1375-85. PubMed ID: 26297712
[TBL] [Abstract][Full Text] [Related]
12. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
13. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
[TBL] [Abstract][Full Text] [Related]
14. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
Liu Y; Zugazagoitia J; Ahmed FS; Henick BS; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
Clin Cancer Res; 2020 Feb; 26(4):970-977. PubMed ID: 31615933
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas.
Aslan K; Turco V; Blobner J; Sonner JK; Liuzzi AR; Núñez NG; De Feo D; Kickingereder P; Fischer M; Green E; Sadik A; Friedrich M; Sanghvi K; Kilian M; Cichon F; Wolf L; Jähne K; von Landenberg A; Bunse L; Sahm F; Schrimpf D; Meyer J; Alexander A; Brugnara G; Röth R; Pfleiderer K; Niesler B; von Deimling A; Opitz C; Breckwoldt MO; Heiland S; Bendszus M; Wick W; Becher B; Platten M
Nat Commun; 2020 Feb; 11(1):931. PubMed ID: 32071302
[TBL] [Abstract][Full Text] [Related]
16. Firing Up Cold Tumors.
Cheng WC; Ho PC
Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
19. Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.
Moufarrij S; Srivastava A; Gomez S; Hadley M; Palmer E; Austin PT; Chisholm S; Diab N; Roche K; Yu A; Li J; Zhu W; Lopez-Acevedo M; Villagra A; Chiappinelli KB
Sci Rep; 2020 Feb; 10(1):3470. PubMed ID: 32103105
[TBL] [Abstract][Full Text] [Related]
20. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
